Move to topTop
October 03, 2022
Terumo Aortic today announced that the United States Centers for Medicare and Medicaid Services (CMS) has granted approval of a New Technology Add-on Payment (NTAP) for Terumo Aortic’s Thoraflex Hybrid Device under the Inpatient Prospective Payment System (IPPS).

Thoraflex Hybrid is the first of its kind device used in Frozen Elephant Trunk (FET) repair in the United States. It was granted Breakthrough Device Designation by the Food and Drug Administration (FDA) in 2020 followed by FDA approval for commercial sale in the United States earlier this year. This innovative hybrid device allows patients with suitably limited disease to be treated in a single stage procedure rather than two procedures which has previously been the conventional pathway in the United States for this group of patients.

The add-on payment will allow hospitals to be reimbursed for the incremental costs relating to the implantation of the Thoraflex Hybrid Frozen Elephant Trunk (FET) device to support the treatment of patients with complex aortic arch disease – this is in addition to the Diagnosis Related Group (DRG) reimbursement.

The add-on payment is effective in CMS’ FY23 fiscal year, starting on 1 October 2022 and has been assigned the maximum new technology add-on payment – 65% of the average cost of the technology, for a case involving the use of the Thoraflex Hybrid Device.

Jeffrey Mifek, Global Vice President of Clinical and Medical Affairs for Terumo Aortic commented: “We are delighted to have received this approval from CMS and it represents an important milestone for Terumo Aortic. The add-on payment provides further evidence that the Thoraflex Hybrid device significantly improves overall patient outcomes, compared to other available treatments.”

Thoraflex Hybrid received CE Mark approval in 2012 with more than 13,000 devices sold commercially around the world over the past 10 years. This device is integral to Terumo Aortic’s market-leading portfolio of surgical, endovascular and hybrid devices to treat every segment of the aorta.

About Terumo

Terumo (TSE: 4543) is a global leader in medical technology and has been committed to “Contributing to Society through Healthcare” for 100 years. Based in Tokyo and operating globally, Terumo employs more than 28,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large.

Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future events or performance. Accordingly, it should be noted that actual results may differ from those forecasts or projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition.

 

Information about products (including products currently in development) included in this material is not intended to constitute an advertisement or medical advice.